Skip to content

Contact +44 (0) 20 7060 7474 email us

Medical Devices

United States Drug Delivery Devices Investment Opportunities

Analysis and Forecasts to 2012

Publication Date September 2008
Publisher Global Markets Direct
Product Type Report
Pages 219
ISBN Number not applicable
Product Code GMD01506

Price

£1,960.00
approximately: $3,002 | €2,184

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

This report is an essential source for in-depth information and data relating to the USA drug delivery devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the drug delivery devices in USA

Scope

  • The report provides drug delivery devices information broken down into detailed categories and segments in United States.
  • Total revenues, products sold, end users, and average pricing.
  • Market shares of all the key competitors.
  • Key pipeline products that are set to shape the market, broken down by sector.
  • Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
  • Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
  • Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
  • Key mergers and acquisitions, partnerships, private equity investments and IPOs.
  • Customer, hospitals and physicians data.

Reasons to buy

  • Gain a strong understanding of the drug delivery devices market in United States.
  • Evaluate and compare the attractiveness of the market in the country.
  • Identify growth segments and opportunities in each industry sector within the country.
  • Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
  • Analyze the competitiveness of the market in the country and identify hotspots.
  • Develop strategies based on the latest product, brand, expansion and research and development news in the country.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
  • Identify and analyze the strengths and weaknesses of the industry incumbents in the country.

Contents

  • 1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
    • 2.2 Definitions
      • 2.2.1 Drug delivery devices
        • 2.2.1.1 Needle-free Injections
        • 2.2.1.2 Inhalation Systems
        • 2.2.1.3 Infusion Systems
  • 3 Healthcare Sector Review
    • 3.1 Healthcare Expenditure
    • 3.2 Healthcare Infrastructure
      • 3.2.1 Healthcare Personnel Data
      • 3.2.2 Healthcare Facilities Data
  • 4 Drug Delivery Devices in United States
    • 4.1 Drug Delivery Devices Overall Revenues (2000-2012)
    • 4.2 Drug Delivery Devices Overall Volume (2000-2012)
    • 4.3 Drug Delivery Devices Overall Company Shares (2005-2006)
  • 5 Inhalation System in United States
    • 5.1 Inhalation Systems Overall Revenues (2000-2012)
      • 5.1.1 Metered Dose Inhalation Systems Overall Revenues (2000-2012)
      • 5.1.2 Dry Powder Inhalation Systems Overall Revenues (2000-2012)
    • 5.2 Inhalation Systems Overall Volume (2000-2012)
      • 5.2.1 Metered Dose Inhalation Systems Overall Volume (2000-2012)
      • 5.2.2 Dry Powder Inhalation Systems Overall Volume (2000-2012)
    • 5.3 Inhalation Systems Average Price (2000-2012)
      • 5.3.1 Metered Dose Inhalation Systems Average Price (2000-2012)
      • 5.3.2 Dry Powder Inhalation Systems Average Price (2000-2012)
    • 5.4 Inhalation Systems Distribution Share (2005-2006)
    • 5.5 Inhalation Systems Company Share (2005-2006)
  • 6 Infusion System in United States
    • 6.1 Infusion Systems Overall Revenues (2000-2012)
      • 6.1.1 Infusion Disposable Sets Infusion System Overall Revenues (2000-2012)
      • 6.1.2 Infusion Pumps Infusion System Overall Revenue (2000-2012)
      • 6.1.3 Syringe Pumps Infusion System Overall Revenue (2000-2012)
    • 6.2 Infusion Systems Overall Volume (2000-2012)
      • 6.2.1 Infusion Disposable Sets Overall Volume (2000-2012)
      • 6.2.2 Infusion Pumps Overall Volume (2000-2012)
      • 6.2.3 Syringe Pumps Overall Volume (2000-2012)
    • 6.3 Infusion Systems Average Price (2000-2012)
      • 6.3.1 Infusion Pumps Average Price (2000-2012)
      • 6.3.2 Syringe Pumps Average Price (2000-2012)
      • 6.3.3 Infusion Disposable Sets Average Price (2000-2012)
    • 6.4 Infusion Systems Distribution Share (2005-2006)
    • 6.5 Infusion Systems Company Share (2005-2006)
  • 7 Needle Free Injections in United States
    • 7.1 Needle Free Injections Overall Revenue (2000-2012)
    • 7.2 Needle Free Injections Category Volume (2000-2012)
    • 7.3 Needle Free Injections Average Price (2000-2012)
    • 7.4 Needle Free Injections Distribution Share (2005-2006)
    • 7.5 Needle Free Injections Company Share (2005-2006)
  • 8 AstraZeneca PLC Company Profile
    • 8.1 Company Overview
    • 8.2 Business Overview
      • 8.2.1 Products
      • 8.2.2 History
    • 8.3 Locations And Subsidiaries
    • 8.4 Financial Deals Landscape
      • 8.4.1 AstraZeneca Completes $6,900 Million Private Placement
      • 8.4.2 AstraZeneca Acquires MedImmune
      • 8.4.3 AstraZeneca Acquires Biologics Manufacturing Facility From DSM Biologics
      • 8.4.4 AstraZeneca Acquires Arrow Therapeutics
      • 8.4.5 AstraZeneca Signs An Agreement With Palatin Technologies
      • 8.4.6 AstraZeneca Signs An Agreement With Bristol-Myers Squibb
      • 8.4.7 AstraZeneca Signs An Agreement With Cubist Pharmaceuticals
      • 8.4.8 AstraZeneca Signs An Agreement With Par Pharmaceutical
      • 8.4.9 Schering Signs An Agreement With AstraZeneca
      • 8.4.10 AstraZeneca Signs An Agreement With Pozen
      • 8.4.11 AstraZeneca Signs An Agreement With Abbott
      • 8.4.12 AstraZeneca To Sell Its U.S Anaesthetic and Analgesic Product Portfolio To Abraxis BioScience
      • 8.4.13 AstraZeneca Acquires KuDOS Pharmaceuticals
      • 8.4.14 AstraZeneca Acquires A Stake In Protherics
      • 8.4.15 AstraZeneca Signs An Agreement With Targacept
      • 8.4.16 AstraZeneca Signs An Agreement With AtheroGenics
      • 8.4.17 AstraZeneca UK Signs An Agreement With Protherics
      • 8.4.18 AstraZeneca Signs An Agreement With Bayer Schering Pharma Aktiengesellschaft
      • 8.4.19 AstraZeneca Signs An Agreement With Astex Therapeutics
      • 8.4.20 AstraZeneca Signs An Agreement With Avanir Pharmaceuticals
      • 8.4.21 AstraZeneca And Royal Cosun Sells Joint Venture Advanta To Syngenta
      • 8.4.22 AstraZeneca Completes Private Placement Of $750 million
      • 8.4.23 AstraZeneca Prices EUR750 Million Private Placement
      • 8.4.24 AstraZeneca Prices Sterling Bond GBP350 Million And Euro750 Million Eurobond Private Placement
    • 8.5 Recent Developments
      • 8.5.1 Feb 22, 2008: AstraZeneca To Appeal Judgment In Alabama Medical Pricing Case
      • 8.5.2 Feb 18, 2008: AstraZeneca Appoints Non-Executive Director
      • 8.5.3 Dec 12, 2007: AstraZeneca Files Patent Infringement Actions in Response to Crestor ANDAs
      • 8.5.4 Sep 28, 2007: AstraZeneca Appoints New CFO
      • 8.5.5 Jul 25, 2007: AstraZeneca Appoints New Board Member
      • 8.5.6 Jun 06, 2007: AstraZeneca CFO Resigns
      • 8.5.7 Feb 22, 2007: AstraZeneca To Invest $120 Miilion For R&D In Macclesfield Site
      • 8.5.8 Jan 30, 2007: Philips And Leading Healthcare Companies Join For Major Research And Development
      • 8.5.9 Jan 22, 2007: AstraZeneca Makes $100 Million Research Investment In Boston
  • 9 GlaxoSmithKline plc Company Profile
    • 9.1 Company Overview
    • 9.2 Business Overview
      • 9.2.1 Products
      • 9.2.2 History
    • 9.3 Locations And Subsidiaries
  • 10 3M Company Profile
    • 10.1 Company Overview
    • 10.2 Business Overview
      • 10.2.1 Consumer and Office
      • 10.2.2 Display and Graphics
      • 10.2.3 Electro and Communications
      • 10.2.4 Health Care
      • 10.2.5 Industrial and Transportation
      • 10.2.6 Safety, Security and Protection Services
      • 10.2.7 Products
    • 10.3 Value Chain Analysis
      • 10.3.1 Manufacturing
      • 10.3.2 Product Development
      • 10.3.3 Sales and Marketing
    • 10.4 SWOT Analysis
      • 10.4.1 3M Company Strengths
      • 10.4.2 3M Company Weaknesses
      • 10.4.3 3M Company Opportunities
      • 10.4.4 3M Company Threats
    • 10.5 Financial and Operational Review
    • 10.6 Locations And Subsidiaries
  • 11 Baxter International Company Profile
    • 11.1 Company Overview
    • 11.2 Business Overview
      • 11.2.1 BioScience
      • 11.2.2 Medication Delivery
      • 11.2.3 Renal
      • 11.2.4 Products
      • 11.2.5 History
    • 11.3 Value Chain Analysis
      • 11.3.1 Manufacturing
      • 11.3.2 Product Development
      • 11.3.3 Sales and Marketing
    • 11.4 SWOT Analysis
      • 11.4.1 Baxter International Inc. Strengths
      • 11.4.2 Baxter International Inc. Weaknesses
      • 11.4.3 Baxter International Inc. Opportunities
      • 11.4.4 Baxter International Inc. Threats
    • 11.5 Financial and Operational Review
    • 11.6 Locations And Subsidiaries
    • 11.7 Baxter International Inc. Pipeline Products
      • 11.7.1 Next-Generation Home Hemodialysis Machine
        • 11.7.1.1 Product Overview
        • 11.7.1.2 Product Description
        • 11.7.1.3 Product Status
        • 11.7.1.4 Product Milestone
  • 12 Hospira Company Profile
    • 12.1 Company Overview
    • 12.2 Business Overview
      • 12.2.1 Injectable Pharmaceutical Custom Manufacturing Services Product Category
      • 12.2.2 Other products, including critical care devices Product Category
      • 12.2.3 Specialty Injectable Pharmaceuticals Product Category
      • 12.2.4 Products
    • 12.3 History
    • 12.4 Value Chain Analysis
      • 12.4.1 Manufacturing
      • 12.4.2 Product Development
      • 12.4.3 Sales and Marketing
    • 12.5 SWOT Analysis
      • 12.5.1 Hospira, Inc. Strengths
      • 12.5.2 Hospira, Inc. Weaknesses
      • 12.5.3 Hospira, Inc. Opportunities
      • 12.5.4 Hospira, Inc. Threats
    • 12.6 Financial and Operational Review
    • 12.7 Locations And Subsidiaries
  • 13 Regulation System
    • 13.1 Medical Equipment Approval Process
      • 13.1.1 Pre-market Approval Process
      • 13.1.2 Intended use and Indications for use
      • 13.1.3 Predicate Device
      • 13.1.4 Safe and Effective
      • 13.1.5 Other Category Devices
      • 13.1.6 Post-Market Approval Process
      • 13.1.7 Compliance and Enforcement
      • 13.1.8 Registration Fee
      • 13.1.9 Approval Time
  • 14 Pricing and Reimbursement
    • 14.1 Government Policies
    • 14.2 Private Insurance
    • 14.3 Diagnosis Related Groups (DRG)
  • 15 Distribution Structure
    • 15.1 Distribution Structure
  • 16 Financial Deals Landscape
    • 16.1 Private Equity
      • 16.1.1 Warburg Pincus Acquires Lifecore Biomedical
    • 16.2 Venture Financing
      • 16.2.1 POINT Biomedical Secures $25 Million In Venture Financing
      • 16.2.2 Medipacs Secures $1.65 Million In Financing Round
      • 16.2.3 AcelRx Pharmaceuticals Secures $20.21 Million In Venture Financing
      • 16.2.4 TyRx Pharma Secures $25 Million In Venture Financing
      • 16.2.5 Oriel Therapeutics Secures $23 Million In Series C Funding
    • 16.3 IPO
      • 16.3.1 MannKind Corporation Completes Private Placement Of $250 Million
      • 16.3.2 Delcath Systems Completes Private Placement Of $14.2 Million
    • 16.4 Debt Offerings
      • 16.4.1 Bioject Medical Completes Private Placement $1.21 Million
    • 16.5 Partnership
      • 16.5.1 Lupin Enters Into An Agreement With Forest Laboratories
      • 16.5.2 Aethlon Medical And Delcath Systems Form Joint Venture
    • 16.6 Asset Transactions
      • 16.6.1 Orthofix International Sells Its Pain Care Assets To LMA International
      • 16.6.2 Boston Scientific Sells Auditory Business And Drug Pump Development Program To Former Shareholders Of Advanced Bionics
  • 17 Recent Developments
    • 17.1 Strategy And Business Planning
      • 17.1.1 Sep 02, 2008: Alpha Innotech And GE Healthcare Announce Strategic Alliance Partnership
      • 17.1.2 Aug 28, 2008: 3M Acquires Texas Based Polyfoam
      • 17.1.3 Apr 08, 2008: BD Opens New Manufacturing Facility In Suzhou, China
    • 17.2 Corporate Communications
      • 17.2.1 May 29, 2008: Alexza Appoints VP, International Development Operations
      • 17.2.2 May 22, 2008: Nektar Appoints New COO
      • 17.2.3 May 19, 2008: Alexza Appoints New President To Its subsidiary
      • 17.2.4 May 15, 2008: Sepracor Appoints New CFO
      • 17.2.5 May 15, 2008: Sepracor CFO To Resign
      • 17.2.6 May 15, 2008: Alexza Appoints New Vice President, Quality
      • 17.2.7 May 13, 2008: Vyteris Appoints President And CFO
      • 17.2.8 May 13, 2008: Hospira Expands Board Of Directors
      • 17.2.9 May 08, 2008: Inovio Elects New Director
      • 17.2.10 May 06, 2008: Echo Appoints Medical Advisory Board Member
      • 17.2.11 Apr 02, 2008: Duska Appoints Scientific Advisory Board Member
      • 17.2.12 Mar 18, 2008: BD Elects Vice Chairman And Board Member
    • 17.3 Legal and Regulatory
      • 17.3.1 Aug 19, 2008: Coughlin Stoia Files Class Action Law Suit Against Inyx
    • 17.4 Product News
      • 17.4.1 Sep 09, 2008: Navilyst Medical Introduces New EZ Huber Safety Infusion Set
  • 18 Appendix
    • 18.1 Methodology
    • 18.2 Currency Conversion
    • 18.3 Contact Us
    • 18.4 Disclaimer
  • 1 List of Tables
    • Table 1: United States Healthcare Expenditure, 2003-2010
    • Table 2: United States Healthcare Expenditure by Age (per person), 2000-2003
    • Table 3: United States Healthcare Expenditure by Sex (per person), 2000-2003
    • Table 4: United States Healthcare Expenditure by Race (per person), 2000-2003
    • Table 5: United States Personal Healthcare Expenditure by Type, 2000-2004
    • Table 6: United States Personal Healthcare Expenditure by Source, 2000-2004
    • Table 7: Total Number of Doctors in the United States, 2003-2010
    • Table 8: Number of Doctors by Specialty in the United States, 2003-2010
    • Table 9: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004
    • Table 10: Doctors by Region (Number per 10,000 Civilian Population), 2002-2004 (Cont.)
    • Table 11: Total Hospitals in the United States, 2000-2004
    • Table 12: Community Hospitals by Number of Beds in the United States, 2000-2004
    • Table 13: Number of Hospital Beds in the United States, 2000-2004
    • Table 14: Number of Hospital Beds by Range in the United States, 2000-2004
    • Table 15: Drug Delivery Devices, United States, Overall Revenues ($ mn), 2000-2012
    • Table 16: Drug Delivery Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 17: Drug Delivery Devices, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 18: Drug Delivery Devices, United States, Category Revenues ($ mn), 2000-2012
    • Table 19: Drug Delivery Devices, United States, Category Revenues ($ mn), Historic, 2000-2007
    • Table 20: Drug Delivery Devices, United States, Category Revenues ($ mn), Forecast, 2007-2012
    • Table 21: Drug Delivery Devices, United States, Category Volume (Units), 2000-2012
    • Table 22: Drug Delivery Devices, United States, Category Volume (Units), Historic, 2000-2007
    • Table 23: Drug Delivery Devices, United States, Category Volume (Units), Forecast, 2007-2012
    • Table 24: Drug Delivery Devices, United States, Overall, Company Share by Revenue ($ mn), 2005-2006
    • Table 25: Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 26: Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 27: Inhalation Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 28: Inhalation Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 29: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 30: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 31: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 32: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2000-2007
    • Table 33: Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 34: Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 35: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 36: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 37: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 38: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 39: Metered Dose Inhalation Systems, United States, Average Price ($), Historic, 2000-2007
    • Table 40: Metered Dose Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012
    • Table 41: Dry Powder Inhalation Systems, United States, Average Price ($), Historic, 2000-2007
    • Table 42: Dry Powder Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012
    • Table 43: Inhalation Systems, United States, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 44: Inhalation Systems, United States, Company Share by Revenue ($ mn), 2005-2006
    • Table 45: Infusion Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 46: Infusion Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 47: Infusion Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Table 48: Infusion Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Table 49: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 50: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 51: Infusion Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 52: Infusion Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 53: Syringe Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 54: Syringe Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 55: Infusion Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 56: Infusion Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 57: Infusion Disposable Sets, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 58: Infusion Disposable Sets, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 59: Infusion Pumps, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 60: Infusion Pumps, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 61: Syringe Pumps, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 62: Syringe Pumps, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 63: Infusion Pumps, United States, Average Price ($), Historic, 2000-2007
    • Table 64: Infusion Pumps, United States, Average Price ($), Forecast, 2007-2012
    • Table 65: Syringe Pumps, United States, Average Price ($), Historic, 2000-2007
    • Table 66: Syringe Pumps, United States, Average Price ($), Forecast, 2007-2012
    • Table 67: Infusion Disposable Sets, United States, Average Price ($), Historic, 2000-2007
    • Table 68: Infusion Disposable Sets, United States, Average Price ($), Forecast, 2007-2012
    • Table 69: Infusion Systems, United States, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 70: Infusion Systems, United States, Company Share by Revenue ($ mn), 2005-2006
    • Table 71: Needle Free Injections, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Table 72: Needle Free Injections, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Table 73: Needle Free Injections, United States, Overall Volume (Units), Historic, 2000-2007
    • Table 74: Needle Free Injections, United States, Overall Volume (Units), Forecast, 2007-2012
    • Table 75: Needle Free Injections, United States, Average Price ($), Historic, 2000-2007
    • Table 76: Needle Free Injections, United States, Average Price ($), Forecast, 2007-2012
    • Table 77: Needle Free Injections, United States, Distribution Share by Revenue ($ mn), 2005-2006
    • Table 78: Needle Free Injections, United States, Company Share by Revenue ($ mn), 2005-2006
    • Table 79: AstraZeneca PLC, Subsidiaries
    • Table 80: GlaxoSmithKline plc, Subsidiaries
    • Table 81: 3M Company, SWOT Analysis, 2006
    • Table 82: 3M Company, Financial Statements, USD Million, 2002-2006
    • Table 83: 3M Company, Financial Ratios, USD Million, 2002-2006
    • Table 84: 3M Company, Subsidiaries
    • Table 85: Baxter International Inc., SWOT Analysis, 2006
    • Table 86: Baxter International Inc., Financial Statements, USD Million, 2002-2006
    • Table 87: Baxter International Inc., Financial Ratios, USD Million, 2002-2006
    • Table 88: Baxter International Inc., Other Locations
    • Table 89: Baxter International Inc., Subsidiaries
    • Table 90: Hospira, Inc., SWOT Analysis, 2006
    • Table 91: Hospira, Inc., Financial Statements, USD Thousand, 2002-2006
    • Table 92: Hospira, Inc., Financial Ratios, USD Thousand, 2002-2006
    • Table 93: Hospira, Inc., Other Locations
    • Table 94: Medical Equipment Registration Fee in United States, 2007
    • Table 95: Medical Device Approval Time in United States, 2004
    • Table 96: Currency Conversion from USD to Local Currency at 2007 Constant Rate
    • 1.2 List of Figures
    • Figure 1: United States, Healthcare Expenditure by Source, 2003
    • Figure 2: United States, Healthcare Infrastructure, Top Level View, 2007
    • Figure 3: Healthcare Expenses Segmentation by End User, 2003
    • Figure 4: Drug Delivery Devices, United States, Overall Revenues ($ mn), 2000-2012
    • Figure 5: Drug Delivery Devices, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 6: Drug Delivery Devices, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 7: Drug Delivery Devices, United States, Category Revenues ($ mn), 2000-2012
    • Figure 8: Drug Delivery Devices, United States, Category Revenues ($ mn), Historic, 2000-2007
    • Figure 9: Drug Delivery Devices, United States, Category Revenues ($ mn), Forecast, 2007-2012
    • Figure 10: Drug Delivery Devices, United States, Overall Company Share (%), 2006
    • Figure 11: Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 12: Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 13: Inhalation Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 14: Inhalation Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 15: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 16: Metered Dose Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 17: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 18: Dry Powder Inhalation Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 19: Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 20: Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 21: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 22: Metered Dose Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 23: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 24: Dry Powder Inhalation Systems, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 25: Metered Dose Inhalation Systems, United States, Average Price ($), Historic, 2000-2007
    • Figure 26: Metered Dose Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012
    • Figure 27: Dry Powder Inhalation Systems, United States, Average Price ($), Historic, 2000-2007
    • Figure 28: Dry Powder Inhalation Systems, United States, Average Price ($), Forecast, 2007-2012
    • Figure 29: Inhalation Systems, United States, Distribution Share (%), 2005-2006
    • Figure 30: Inhalation Systems, United States, Company Share (%), 2006
    • Figure 31: Infusion Systems, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 32: Infusion Systems, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 33: Infusion Systems, United States, Revenue by Segment ($ mn), Historic, 2000-2007
    • Figure 34: Infusion Systems, United States, Revenue by Segment ($ mn), Forecast, 2007-2012
    • Figure 35: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 36: Infusion Disposable Sets, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 37: Infusion Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 38: Infusion Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 39: Syringe Pumps, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 40: Syringe Pumps, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 41: Infusion Disposable Sets, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 42: Infusion Disposable Sets, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 43: Infusion Pumps, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 44: Infusion Pumps, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 45: Syringe Pumps, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 46: Syringe Pumps, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 47: Infusion Pumps, United States, Average Price ($), Historic, 2000-2007
    • Figure 48: Infusion Pumps, United States, Average Price ($), Forecast, 2007-2012
    • Figure 49: Syringe Pumps, United States, Average Price ($), Historic, 2000-2007
    • Figure 50: Syringe Pumps, United States, Average Price ($), Forecast, 2007-2012
    • Figure 51: Infusion Disposable Sets, United States, Average Price ($), Historic, 2000-2007
    • Figure 52: Infusion Disposable Sets, United States, Average Price ($), Forecast, 2007-2012
    • Figure 53: Infusion Systems, United States, Distribution Share (%), 2006
    • Figure 54: Infusion Systems, United States, Company Share (%), 2006
    • Figure 55: Needle Free Injections, United States, Overall Revenues ($ mn), Historic, 2000-2007
    • Figure 56: Needle Free Injections, United States, Overall Revenues ($ mn), Forecast, 2007-2012
    • Figure 57: Needle Free Injections, United States, Overall Volume (Units), Historic, 2000-2007
    • Figure 58: Needle Free Injections, United States, Overall Volume (Units), Forecast, 2007-2012
    • Figure 59: Needle Free Injections, United States, Average Price ($), Historic, 2000-2007
    • Figure 60: Needle Free Injections, United States, Average Price ($), Forecast, 2007-2012
    • Figure 61: Needle Free Injections, United States, Distribution Share (%), 2006
    • Figure 62: Needle Free Injections, United States, Company Share (%), 2006
    • Figure 63: 3M Company, Value Chain Analysis
    • Figure 64: Baxter International Inc., Value Chain Analysis
    • Figure 65: Hospira, Inc., Value Chain Analysis
    • Figure 66: Medical Equipment Approval Process in the United States, 2007
    • Figure 67: PMA Approval Process in the United States, 2007
    • Figure 68: The 510(k) Approval Process for Medical Devices in the United States, 2007
    • Figure 69: Reimbursement Structure in the United States, 2007
    • Figure 70: Distribution Structure of Medical Equipment in the United States, 2006
Product Features / Use
Scope Expert Insight/Opinion
Profiles In-depth Company Insight
Features Primary Research Data